Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug;11(8):4151-4158.
doi: 10.4103/jfmpc.jfmpc_2432_21. Epub 2022 Aug 30.

Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment

Garima Mamgain  1 , Praveen K Singh  2 , Priyanka Patra  2 , Manisha Naithani  2 , Uttam K Nath  1
Affiliations
Review

Diffuse large B-cell lymphoma and new insights into its pathobiology and implication in treatment

Garima Mamgain et al. J Family Med Prim Care. 2022 Aug.

Abstract

The most common non-Hodgkin lymphoma (NHL) subtype is diffuse large B-cell lymphoma (DLBCL). It accounts for roughly 30% of all cases of NHL affecting both nodal and extra nodal sites. There are molecular subtypes of DLBCL, germinal centre subtype (GCB), and activated B-cell (ABC), based on gene expression profiling (GEP), in accumulation to distinct morphological and clinicopathological subtypes. To prognosticate patients, the International Prognostication Index (IPI) and its variants are used. In ABC type DLBCL, limited stage disease is treated with a combination of abbreviated systemic chemotherapy (three cycles) and field radiation therapy. Although advanced stage disease is treated with a full course of chemotherapy as well as novel agents (Bortezomib, Ibrutinib, Lenalidomide). In this review study, we looked at the role of multiple aspects of genetic and microenvironment changes which have effects in DLBCL tumours.

Keywords: Activated B-cell; diffuse large B-cell lymphoma; germinal centre; rituximab.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
DLBCL classification. DLBCL: Diffuse large B-cell lymphoma; ABC: Activated B cell-like; GCB: Germinal centre B-cell; Double hit ≠ double expressors (most “double hit” cases are GCB DLBCL; most double expressors are ABC DLBCL)
See this image and copyright information in PMC

References

    1. Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29:1452–7. - PubMed
    1. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–47. - PubMed
    1. Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–23. - PMC - PubMed
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. Lyon, France: International Agency for Research on Cancer; 2008. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.
    1. Sjö LD, Poulsen CB, Hansen M, Møller MB, Ralfkiaer E. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: Identification of prognostic subgroups. Eur J Haematol. 2007;79:501–7. - PubMed